Results 51 to 60 of about 16,194 (165)

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources

Revista de Gastroenterología de México (English Edition), 2018
Aims: To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access.
S. Marciano, L. Haddad, S.M. Borzi, C. D’Amico, L.A. Gaite, M.V. Aubone, M.E. Sirotinsky, N. Ratusnu, M.S. Frola, M.C. Aparicio, B. Ríos, M.N. Anselmo, R. Hansen, S. De Filippi, C. García Dans, L. de Labra, M.A. Peche, T.M. Strella, M. Ibáñez Duran, M.B. García Rosales, M. Dirchwolf, O.A. Galdame, A.C. Gadano   +22 more
doaj   +1 more source

Drug-drug interactions with direct-acting antivirals — less is more [PDF]

Clinical and Molecular Hepatology, 2021
Grace Lai-Hung Wong
doaj   +1 more source

Hepatitis C in Children—An Asia–Pacific Concise Perspective

Pathogens
Since the discovery of hepatitis C virus (HCV) in 1989, we now have curative treatment options with direct-acting antiviral therapies. By increasing the rate of treatment and reducing transmission, the eradication of HCV is potentially achievable ...
Lynette Goh, Winita Hardikar
doaj   +1 more source

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

Journal of Virus Eradication, 2018
Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to ...
Andrew Hill, Loai Tahat, Mohammed Khalil Mohammed, R.abab Fayez Tayyem, Giten Khwairakpam, Sanjay Nath, James Freeman, Ismahane Benbitour, Sherine Helmy   +8 more
doaj   +1 more source

Direct-Acting Antiviral Agents for HCV Infection [PDF]

Journal of Clinical and Experimental Hepatology, 2018
Madhumita, Premkumar, Radha K, Dhiman
openaire   +2 more sources

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents

Journal of Medical Microbiology and Infectious Diseases, 2020
Introduction: A new pathological form of HCV named as occult HCV infection (OCI) has been recently characterized by the presence of HCV RNA in liver biopsy and/or peripheral blood mononuclear cell specimens (PBMCs) and the absence of detectable ...
Elnaz Agi, Saber Asghari, Ali Namvar, Niloofar Khairkhah, Niloofar Naderi, Ali Anvar, Alireza Azizi Saraji, Azam Bolhassani   +7 more
doaj  

Norovirus antiviral discovery: host-modulators and direct-acting antivirals

, 2018
Human norovirus is a leading cause of acute gastroenteritis (AGE) worldwide and is estimated to be responsible for over 200,000 deaths each year. Norovirus infections are estimated to cost $60 billion in societal costs globally each year. Yet despite the substantial health and economic burden of norovirus, there is no vaccine or norovirus-specific ...
openaire   +2 more sources

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

Infection and Drug Resistance, 2019
Georg von Massow,1 Damir Garcia-Cehic,1,2 Josep Gregori,1–3 Francisco Rodriguez-Frias,2,4 María Dolores Macià,5 Ana Escarda,6 Juan Ignacio Esteban,1–2,7 Josep Quer1–2,71Liver Unit, Liver Diseases – Viral Hepatitis ...
von Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, Esteban JI, Quer J   +7 more
doaj  

Small molecule direct-acting antivirals for treatment of mpox

Antiviral Research
In 2022 and 2024, outbreaks of mpox disease caused by two different clades of MPXV resulted in the World Health Organization (WHO) declaring two public health emergencies of international concern (PHEIC). Different clades/subclades/lineages of MPXV can have substantially different pathogenicity and transmission characteristics.
E. Randall Lanier, Richard L. Mackman, Lee Ruggiero, James F. Demarest, John C. Pottage   +4 more
openaire   +2 more sources

Evaluating the effectiveness of a population-level health intervention to increment HCV treatment coverage in tuscany region, Italy: An interrupted time series analysis.

PLoS ONE
Worldwide, an estimated 57.8 million people are chronically infected with the Hepatitis C virus (HCV). The advent of direct-acting antivirals (DAAs) has made possible the definition of elimination targets by 2030.
Chiara Seghieri, Luca Ceccarelli, Costanza Tortù, Lara Tavoschi   +3 more
doaj   +1 more source